<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00382512</url>
  </required_header>
  <id_info>
    <org_study_id>ACD2244g</org_study_id>
    <nct_id>NCT00382512</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Placebo-Controlled, Single-Blind, Parallel-Group Study to Evaluate the Effects of 12 Weekly Subcutaneous Doses of 1.0 mg/kg Efalizumab on Immune Responses in Subjects With Moderate Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is a Phase I, randomized, placebo-controlled, single blind, parallel group,
      single-center study designed to evaluate immune responses during and after administration of
      12 weekly SC doses of 1.0 mg/kg efalizumab in subjects with moderate plaque psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean concentrations of anti-&lt;phi&gt;X174 antibodies in the FU period 2 weeks after the FU Day 70 vaccinations in Group A compared with mean antibody concentrations 2 weeks after the Treatment Day 63 vaccination in Group C</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean concentrations of anti-&lt;phi&gt;X174 antibodies in the FU period 2 weeks after the FU Day 70 vaccination in Group B compared with mean antibody concentrations 2 weeks after the Treatment Day 63 vaccination in Group C.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of mean concentrations of anti-&lt;phi&gt;X174 antibodies 2 weeks after the FU Day 42 vaccination in Group A compared with mean antibody concentrations 2 weeks after the Treatment Day 35 vaccination in Group C</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of mean concentrations of anti-&lt;phi&gt;X174 antibodies 2 weeks after the FU Day 42 vaccination in Group B compared with mean antibody concentrations 2 weeks after the Treatment Day 35 vaccination in Group C</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of mean anti-&lt;phi&gt;X174 concentrations 2 and 4 weeks after the first and 2 and 4 weeks after the second &lt;phi&gt;X174 vaccinations during efalizumab treatment (Group A) compared with placebo (Group C)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of mean concentrations of anti-tetanus IgG during treatment with efalizumab compared with placebo, representing a secondary humoral immune response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterization of anti-pneumococcal antibody concentrations on FU Day 70 after pneumococcal vaccination on FU Day 42 compared with placebo</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with positive skin test reactions to tetanus and Candida-recall antigens on FU Day 77 after washout from efalizumab compared with baseline.</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Plaque Psoriasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raptiva (efalizumab)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Plaque psoriasis covering 8%-15% of the total BSA

          -  Diagnosis of plaque psoriasis for at least 6 months

          -  Body weight of ≤140 kg

          -  18 to 65 years old

          -  For women of childbearing potential and men who may father children, use of an
             acceptable method of contraception to prevent pregnancy and agreement to continue to
             practice an acceptable method of contraception for the duration of their participation
             in the study (the following methods of contraception are acceptable: condom;
             abstinence; oral, implantable or injectable contraceptives by the sexual partner; IUD,
             female condom, diaphragm with spermicide, cervical cap; a sterile sexual partner)

          -  Willingness to hold sun exposure reasonably constant and to avoid use of tanning
             booths or other UV light sources during the study

          -  History of tetanus vaccination

        Exclusion Criteria:

          -  Guttate, erythrodermic, or pustular psoriasis as sole or predominant form of psoriasis

          -  History of severe allergic or anaphylactic reactions to humanized monoclonal
             antibodies or fusion proteins that contain an Ig Fc region

          -  Clinically significant psoriasis exacerbation during screening or at the time of
             enrollment

          -  History of or ongoing uncontrolled bacterial, viral, fungal, or atypical mycobacterial
             infection

          -  History of opportunistic infections (e.g., systemic fungal infections, parasites)

          -  Seropositivity for human immunodeficiency virus (HIV)

          -  Pregnancy or lactation

          -  White blood cell (WBC) count &lt;4000/uL or &gt;14,000/uL

          -  Seropositivity for hepatitis B or C virus

          -  Hepatic enzymes ≥3 times the upper limit of normal

          -  Tetanus or pneumococcal vaccination during the 6 months prior to the start of the
             study (Treatment Day 0) or failure to complete a primary series of tetanus
             immunizations

          -  Known hypersensitivity reaction to tetanus or diphtheria toxoid

          -  Known hypersensitivity to any of the administered vaccinations or their components

          -  History of active tuberculosis (TB) or currently undergoing treatment for TB

          -  Positive purified protein derivative (PPD) (tuberculin) testing at screening (as
             defined by CDC Guidelines, see Appendix C for test assessment criteria and listing of
             high-risk groups)

          -  Presence of malignancy within the past 5 years, including lymphoproliferative
             disorders

          -  Treatment with efalizumab (anti-CD11a) within the last 12 months

          -  Previous administration of &lt;phi&gt;X174

          -  Diagnosis of hepatic cirrhosis, regardless of cause or severity

          -  Serum creatinine ≥2 times the upper limit of normal

          -  Hospital admission for cardiac disease, stroke, or pulmonary disease within the last
             year

          -  History of substance abuse within the last 5 years as judged by the Principal
             Investigator

          -  Any medical condition that, in the judgment of the investigator, would jeopardize the
             subject's safety following exposure to study drug

          -  Systemic therapy for psoriasis (Screening Day -28 through FU Day 98)

          -  Systemic immunosuppressive drugs for any indications (Screening Day -28 through FU Day
             98)

          -  Live virus or bacteria vaccines other than protocol specified (Screening Day -14
             through Treatment Day 84)

          -  Other vaccines or allergy desensitization (must be scheduled at least 14 days prior to
             Treatment Day 0 or after FU Day 98)

          -  Other experimental drugs or treatments (within 90 days or five half-lives, whichever
             is longer, prior to Treatment Day 0 and through FU Day 98)

          -  &lt;beta&gt;-Blockers, angiotensin-converting enzyme (ACE) inhibitors, quinidine,
             antimalarial drugs, or lithium (if clinically indicated, such medications are allowed
             but the dosage should be held constant between Screening Day -28 and Treatment Day 84)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Dummer, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 27, 2006</study_first_submitted>
  <study_first_submitted_qc>September 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2006</study_first_posted>
  <last_update_submitted>September 27, 2006</last_update_submitted>
  <last_update_submitted_qc>September 27, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2006</last_update_posted>
  <keyword>Moderate Plaque Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

